Key result
Valsalva maneuver successfully terminates recurrent drug-refractory VT in a single case report.
Why the study?
The use of Valsalva manoeuvre to terminate ventricular tachycardia is not conventionally recommended due to lack of robust evidence of effectiveness and poor understanding of its mechanism.
Does the Valsalva manoeuvre terminate ventricular tachycardia in a patient with ischaemic heart disease?
Case Report (n=1)
Does the Valsalva manoeuvre terminate ventricular tachycardia in a patient with ischaemic heart disease?
This case report highlights the potential utility of the Valsalva manoeuvre in terminating specific types of ventricular tachycardia, such as those originating from Purkinje fibres.
Should not yet change practice; hypothesis-generating for Valsalva in Purkinje-related VT.
BACKGROUND: Ventricular tachycardia (VT) is often misdiagnosed as supraventricular tachycardia with aberrancy. Twelve-lead electrocardiogram remains a key diagnostic tool to differentiate them while providing insights to aid localization of VT. The use of Valsalva manoeuvre (VM) in terminating VT is not conventionally recommended due to lack of robust evidence of its effectiveness and poor understanding of its mechanism in terminating VT. CASE SUMMARY: A 74-year-old man with history of ischaemic heart disease was admitted with broad complex tachycardia. VT-1 was diagnosed following failed tachycardia termination by adenosine. Haemodynamic compromise necessitated synchronized cardioversion with successful reversion. However, a different VT-2 occurred after cardioversion. VM led to successful termination of VT-2. Subsequently, recurrent episodes of VT-2 occurred with consistent termination by VM. Transthoracic echocardiogram, cardiac magnetic resonance imaging, and a coronary angiogram were performed. Findings suggested that these are likely scar-related VT. VT-1 originated from an anteroseptal scar, whilst VT-2, responsive to VM, likely originated from the Purkinje fibres. Patient remained eurhythmic after Day 1 following amiodarone and beta-blocker initiation. An implantable cardioverter-defibrillator was implanted prior to discharge. DISCUSSION: VM is one of the vagal manoeuvres which are commonly used as initial management of supraventricular tachycardia. Its role in management of VT is obscure. Anecdotal case series recorded its successful use for managing particular VT. Exact mechanism remains elusive although postulated to involve change in cardiac size during strain and release of acetylcholine.
No takes yet. Share an insight, caveat, or question.
Lwin et al. (2021) conducted a case report in Drug-refractory ventricular tachycardia (n=1). Valsalva manoeuvre was evaluated on Termination of ventricular tachycardia. Valsalva manoeuvre successfully and consistently terminated recurrent episodes of drug-refractory ventricular tachycardia likely originating from the Purkinje fibres in a 74-year-old man.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: